Bharatt%2BChowrira%252C%2BPureTech%2BHealth.jpg

Bharatt Chowrira, J.D., Ph.D., has been the President and Chief of Business and Strategy at PureTech Health since March 2017. Prior to joining PureTech Health, Dr. Chowrira was the President of Synlogic, a biopharmaceutical company focused on developing synthetic microbiome-based therapeutics, from September 2015 to February 2017, where he oversaw and managed corporate and business development, alliance management, financial, human resources, intellectual property and legal operations. Prior to joining Synlogic, Dr. Chowrira was the Chief Operating Officer of Auspex Pharmaceuticals from 2013 to 2015, which was acquired by Teva Pharmaceuticals in the Spring of 2015. Previously, he was President and Chief Executive Officer of Addex Therapeutics from 2011 to 2013, a biotechnology company publicly-traded on the SIX Swiss Exchange. Prior to that Dr. Chowrira held various leadership and management positions at Nektar Therapeutics (COO), Merck & Co (VP), Sirna Therapeutics (GC; acquired by Merck &Co) and Ribozyme Pharmaceuticals (Chief Patent Counsel). Dr. Chowrira is currently a member of the board of directors of Akili Interactive and Karuna Pharmaceuticals, Inc. Dr. Chowrira received a JD from the University of Denver’s Sturm College of Law, a PhD in Molecular Biology from the University of Vermont College of Medicine, an MS in Molecular Biology from Illinois State University and a BS in Microbiology from the UAS, Bangalore, India.